false
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Catalog
ENDO 2024: Diabetes Dialogues LIVE | Beyond Inerti ...
The Basis for Weekly Insulin Therapy: Article
The Basis for Weekly Insulin Therapy: Article
Back to course
Pdf Summary
The document discusses the evolution of basal insulin therapy, focusing on the development of extended-release insulins like Insulin Icodec and Insulin Efsitora Alfa for once-weekly administration to improve glycemic control and patient adherence. These newer insulins employ innovative strategies to enhance basal insulin replacement by reducing variability, simplifying dosing regimens, and potentially improving treatment adherence compared to once-daily insulins. Phase 2 and 3 clinical trials have shown comparable glycemic control with lower risk of hypoglycemia and potential benefits in patient satisfaction and body weight control with once-weekly Insulin Icodec. The document also addresses the challenges and benefits of transitioning to weekly insulins, the importance of monitoring glucose responses, managing hypoglycemia, and the potential for combining once-weekly insulins with other therapies like GLP-1 receptor agonists. It underscores the need to address barriers to insulin therapy initiation and intensification to optimize treatment outcomes and improve patient quality of life in diabetes management. The potential impact of these Once-weekly insulins on treatment outcomes and patient quality of life is highlighted as a move towards more convenient and effective insulin therapy options to manage diabetes effectively.
Keywords
basal insulin therapy
extended-release insulins
Insulin Icodec
Insulin Efsitora Alfa
glycemic control
patient adherence
once-weekly administration
hypoglycemia risk
GLP-1 receptor agonists
diabetes management
EndoCareers
|
Contact Us
|
Privacy Policy
|
Terms of Use
CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036
202.971.3636 | 888.363.6274
×